The Basic Principles Of Tyrosinase-IN-12
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To guage a number of intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Major trial targets have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis